Last edition
News about "Pharmaceutical Administration Bureau "
Ascentage Pharma Olverembatinib Gets Approval from ISAF for Commercialization in Macau China
Ascentage Pharma has announced that its BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of the People's Republic of China.
Pharmaceutical Administration Bureau | 08/07/2024 | By Aishwarya | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members